Efficacy and Tolerability in Thai Women
Information source: Bayer
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Menopause
Intervention: Estradiol (Drug); Drospirenone (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Schering Pharma AG, Germany, Medical Affairs, Region Asia/ Pacific, Study Director, Affiliation: +65 6511 6194
Summary
To evaluate the safety, tolerability, and efficacy of Angeliq® in Thai post menopausal women
with hot flushes and other climacteric symptoms.
Clinical Details
Official title: A Multi-Center, Open-Label, Non-Comparative Study Investigating the Efficacy and Tolerability of Angeliq® in Postmenopausal Thai Women With Vasomotor Symptoms Over Three 28-Day Treatment Cycles
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Primary outcome: This study aims to evaluate the safety, tolerability and efficacy of Angeliq® in Thai postmenopausal women with hot flushes and other climacteric and urogenital symptoms.
Detailed description:
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility
Minimum age: 45 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Postmenopausal women with hot flushes
Exclusion Criteria:
- Women with a contraindication for HRT
Locations and Contacts
Additional Information
Starting date: August 2005
Last updated: May 1, 2007
|
